Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma

Bortezomib selectively binds and inhibits the 20S proteasome enzyme’s active sites. This study was conducted to determine the side effects and maximum tolerated dose (MTD) of bortezomib in patients with recurrent malignant glioma. Separate dose escalations were conducted in patients taking or not ta...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Phuphanich, Surasak, Supko, Jeffrey G., Carson, Kathryn A., Grossman, Stuart A., Nabors, L. Burt, Mikkelsen, Tom, Lesser, Glenn, Rosenfeld, Steve, Desideri, Serena, Olson, Jeffrey J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2010
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3811025/
https://ncbi.nlm.nih.gov/pubmed/20213332
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-010-0143-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller